BMS-986504

Phase 2Small molecule

Bristol-Myers Squibb

BMS-986504 is one of 140 small molecule programs targeting Pleural Mesothelioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

139

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pleural MesotheliomaRecruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Metastatic Non Small Cell Lung CancerRecruiting

Glioblastoma WHO Grade IVRecruiting

Pleural MesotheliomaPhase 1

Recruiting

Pancreatic Ductal AdenocarcinomaPhase 2/Phase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 2/Phase 3

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Metastatic Non Small Cell Lung CancerPreclinical

Recruiting

Glioblastoma WHO Grade IVPhase 1

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

BMS-986504

Bristol-Myers Squibb

Phase 2

1 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Vidaza

Bristol-Myers Squibb

Preclinical

1 9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Advanced Solid Tumors

NCT07077434

Q3 2027

Phase 1Recruiting

Glioblastoma WHO Grade IV

NCT06883747

Q2 2029

Phase 1Recruiting

Pleural Mesothelioma

NCT07532902

Phase 2/3Recruiting

Pancreatic Ductal Adenocarcinoma

NCT07076121

Q3 2031

PreclinicalRecruiting

Metastatic Non Small Cell Lung Cancer

NCT07063745

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT07077434·32 enrolled

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06672523·8 enrolled

Metastatic Solid Tumors1 trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07492680·260 enrolled

Pancreatic Cancer1 trial

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Suspended·MM.D. Anderson Cancer Center·Phase 2·NCT07283705·60 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT07076121·470 enrolled

Non-Small Cell Lung Cancer1 trial

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT06855771·130 enrolled

3 more indications

Pleural Mesothelioma1 trial

A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07532902·60 enrolled

Metastatic Non Small Cell Lung Cancer1 trial

A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07063745·590 enrolled

Glioblastoma WHO Grade IV1 trial

A Phase 0/1 Study of BMS-986504, a MTA Cooperative PRMT5 Inhibitor in Recurrent Glioblastoma Participants With MTAP Deleted Tumors Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK-Triggered Expansion Cohort

Recruiting·NNader Sanai·Phase 1·NCT06883747·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for BMS-986504. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986504 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986504. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

BMS-986504

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q2 2029

Q3 2031

Trials by Indication[1]

Advanced Solid Tumors2 trials

Metastatic Solid Tumors1 trial

Pancreatic Cancer1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Pleural Mesothelioma1 trial

Metastatic Non Small Cell Lung Cancer1 trial

Glioblastoma WHO Grade IV1 trial

References

Drug Info

Quick Facts

Related News